Earnings Call update points, page-5

First 5 Last

Share
Profile

Follow
cadrifter

1,247 Posts.

06/05/16

15:48

Post #: 17697675
Share

Originally posted by TDA ↑

Hmmm??:

REGN EC:

"In March we reported positive data from the Phase 3 ODYSSEY ESCAPE study in patients with heterozygous familial hypercholesterolemia who required chronic weekly or bi-weekly apheresis. Apheresis is an invasive, expensive and time-consuming therapy given to the patients with the highest cholesterol levels and the greatest need. Our studies show that Praluent reduced the need for apheresis by 75% compared to placebo and 63% of Praluent patients no longer required apheresis compared to 0% of the patients in the placebo arm. Praluent is the only PCSK9 inhibitor that has been studied in this apheresis setting, which represents some of the most severe hypercholesterolemic patients.

The adverse events that occurred more frequently in the Praluent-treated patients were injection site reactions and myalgia. We expect our Supplemental BLA for the once-monthly dosing regimen of Praluent to be filed in the second quarter, which, if approved, will expand our dosing flexibility options"

Expand

"Heterozygous FH (HeFH). HeFH occurs in 1 in 250 people worldwide." ...

"In the United States alone, an estimated 1.3 million people live with FH. Yet only 10% of them are diagnosed."

https://thefhfoundation.org/about-fh/what-is-fh/

Can't wait for all those adds telling people to ask your doctor if you have HeFH.

UNS Price at posting: 12.3¢ Sentiment: Buy Disclosure: Held
6 Upvote

0 Great analysis

Reply

Top Stories

BDM

Burgundy plunges -20% after turning to layoffs to navigate record-low diamond prices

STN

Saturn brings up seventh straight Apollo Hill upgrade on 'impressive' 300-hole drill run

SER

Strategic Energy extends its QLD copper-gold frontier with Diamantina acquisition

DRO

History repeats for DroneShield investors but carnage so far subdued

AII

A new NASDAQ listing for a key player in the global critical minerals space

HotCopper Highlights: Trigg; Droneshield; Lumos & more

SYR

Syrah jumps +19% as graphite tariff threat spurs optimism down under

PSC

Prospect's Mumbezhi Project puts it at the middle of copper's megatrend. And FQM just bought in

ASX Market Open: Can we squeeze one more record reset into Week 29? | July 18

Listen: HotCopper Wire Podcast 018 – Potatoes, TACOs, and the $120M helicopter heist

First 5 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Earnings Call update points, page-5

Top Stories

Burgundy plunges -20% after turning to layoffs to navigate record-low diamond prices

Saturn brings up seventh straight Apollo Hill upgrade on 'impressive' 300-hole drill run

Strategic Energy extends its QLD copper-gold frontier with Diamantina acquisition

History repeats for DroneShield investors but carnage so far subdued

A new NASDAQ listing for a key player in the global critical minerals space

HotCopper Highlights: Trigg; Droneshield; Lumos & more

Syrah jumps +19% as graphite tariff threat spurs optimism down under

Prospect's Mumbezhi Project puts it at the middle of copper's megatrend. And FQM just bought in

ASX Market Open: Can we squeeze one more record reset into Week 29? | July 18

Listen: HotCopper Wire Podcast 018 – Potatoes, TACOs, and the $120M helicopter heist

Featured News